NeoCARD: Anthracycline-Free Chemoimmunotherapy for Triple-Negative Breast Cancer
This study is testing a new treatment combination for triple-negative breast cancer (TNBC) in patients who cannot receive standard anthracycline-based chemotherapy due to heart conditions. The treatment involves three medicines: carboplatin, paclitaxel, and pembrolizumab (an immunotherapy that helps your immune system fight cancer). Researchers want to see how well this combination shrinks tumors before surgery. The main goal is to measure the pCR rate (pathologic complete response, meaning no cancer cells are found in the breast and lymph nodes after treatment) at 18 weeks. You may be eligible if you have Stage II or IIIA/B TNBC. The study plans to enroll 43 participants, but its current recruitment status is unclear.
- Study design
- This is a single-arm study, meaning all participants receive the same treatment. It plans to enroll 43 participants.
- What's involved
- You would receive carboplatin, paclitaxel, and pembrolizumab for 12-18 weeks. The primary outcome is measured at 18 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 18 weeks after treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
At a glance
Conditions
NCT06845319
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Medical University of South Carolina
Charleston, South Carolinastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Abi Siva, MD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- pCR Rate in TNBC patients18 weeks
To determine the pCR rate in TNBC patients treated with the 12-18 weeks CPP regimen